达托霉素对糖尿病足合并MRSA感染患者炎症指标和基质金属蛋白酶的影响

发布时间：2018-10-15 10:13

【摘要】：目的:探讨达托霉素对糖尿病足(DF)合并耐甲氧西林金黄色葡萄球菌(MRSA)感染患者的影响。方法:选取2型糖尿病DF合并MRSA感染患者179例,按随机数字表法分为达托霉素组(90例)和万古霉素组(89例),两组患者合并纳入感染组,同时选取DF未合并MRSA感染者,纳入未感染组(90例),各组患者均接受DF常规治疗,达托霉素组患者在常规治疗基础上加用达托霉素静脉注射,每次4 mg/kg,1次/d;万古霉素组患者在常规治疗基础上加用万古霉素静脉注射,每次4mg/kg,1次/d。疗程均为2周。结果:治疗后感染组患者白细胞介素(IL)-6、IL-8、基质金属蛋白酶(MMP)-2、MMP-9水平显著降低,基质金属蛋白酶组织抑制因子(TIMP)-1水平显著升高,与治疗前比较,差异均有统计学意义(P0.05);达托霉素组有效率为94.4%,显著高于万古霉素组的71.9%,差异有统计学意义(P0.05)。结论:达托霉素可有效改善DF合并MRSA感染患者机体炎症状态,恢复MMP-2/TIMP-1动态平衡。
[Abstract]:Objective: to investigate the effect of dastomycin on diabetic foot (DF) patients with methicillin-resistant Staphylococcus aureus (MRSA) infection. Methods: 179 patients with type 2 diabetes mellitus (DF) complicated with MRSA infection were randomly divided into two groups: Dastomycin group (90 cases) and vancomycin group (89 cases). 90 patients were included in the uninfected group. The patients in each group received DF routine treatment, and the patients in the daptomycin group received intravenous injection of daptomycin on the basis of routine treatment. The patients in the vancomycin group were treated with vancomycin intravenously on the basis of routine therapy, 4 mg / kg / d. The course of treatment was 2 weeks. Results: after treatment, the levels of IL-8, MMP-9 and MMP-9 of matrix metalloproteinase (MMP) _ 2 in infected patients were significantly decreased, and the level of tissue inhibitor of matrix metalloproteinase (TIMP) _ 1) was significantly increased, compared with that before treatment. The difference was statistically significant (P0.05); the effective rate of Dastomycin group was 94.4, significantly higher than that of vancomycin group 71.9, the difference was statistically significant (P0.05). Conclusion: Dastomycin can effectively improve the inflammatory state of DF patients with MRSA infection and restore the dynamic balance of MMP-2/TIMP-1.
【作者单位】：重庆医药高等专科学校医学技术学院;重庆医药高等专科学校护理学院;重庆市红十字会医院科教科;
【分类号】：R587.2;R515

【共引文献】